Lilly presents new cardiometabolic data at EASD 2026
Findings cover retatrutide weight loss, Foundayo safety, and eloraTZP Phase 2 results across diabetes and obesity treatments.
See the latest news and media coverage for Lilly. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global biopharmaceutical company
lilly.comLast updated
In short: Lilly reported a 48% surge in Q2 revenue to $23 billion and raised its full-year guidance due to demand for its weight-loss drugs.
Findings cover retatrutide weight loss, Foundayo safety, and eloraTZP Phase 2 results across diabetes and obesity treatments.
The transaction allows Lilly to integrate AtaiBeckley's rapid-acting neuroplastogen programs, including BPL-003 for treatment-resistant depression, into its neuroscience pipeline.
The drug lowers major adverse cardiovascular events in adults with type 2 diabetes, based on the SURPASS-CVOT trial results.
Eli Lilly filed six lawsuits against US entities selling the unapproved drug and urges regulators, payment processors, and logistics carriers to disrupt the illicit black market.
Shares of Eli Lilly and Company are trading higher Tuesday following positive previews of its...
Eli Lilly (LLY) stock gains 2% after Citigroup sets a Street-high $1,600 price target and Berenberg upgrades to Buy, citing obesity drug dominance.
Eli Lilly (LLY) said Friday that it has completed its acquisition of AtaiBeckley (ATAI), a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for men...
Global pharmaceutical giants are making a series of massive investments to secure next-generation immunology drugs. AbbVie completed its $10.9 ...
Track Lilly and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Lilly and other trending companies.